REGNRegeneron Pharmaceuticals
Is the business good?
The checks split: earnings fully cash-backed (1.5×), but margins compressing.
Operating profit is fully backed by cash. Conversion is improving vs a year ago.
Negative operating leverage, costs are rising faster than sales, squeezing margins as it grows.
Margin-driven, fat margins on slower asset turns. ROE 14% = margin × turnover × leverage.
Unless marked, from derived.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is REGN?
Regeneron Pharmaceuticals earns 12% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 2.8 points above what the capital costs: growth creates value
- Operating margin
- 25%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Cash conversion
- 1.45×
Cash conversion · 1.35× a year ago · operating cash flow covers the operating profit after tax
- Share count, year on year
- −2.4%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | 42% |
| FY2021 | 56% |
| FY2022 | 39% |
| FY2023 | 31% |
| FY2024 | 28% |
| FY2025 | 25% |
Details›
- Operating margin12 months to Q2 2026
- 25%
- Net margin12 months to Q2 2026
- 28%
- Free cash flow margin
- 24%
- R&D as % of revenue
- 40%
- Revenue, trailing twelve months
- $15.5B
- Free cash flow, trailing twelve months
- $3.76B
- Net income, trailing twelve months
- $4.33B
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 12%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
The closest names by size in the same industry